Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

Authors Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M

Received 29 August 2012

Accepted for publication 6 November 2012

Published 30 January 2013 Volume 2013:8 Pages 79—87


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yevgeniy Samyshkin,1 Michael Schlunegger,2 Susan Haefliger,3 Sabine Ledderhose,3 Matthew Radford1

1IMS Health, Health Economics and Outcomes Research, London, United Kingdom; 2Marketing Specialty Care, 3Medical Department, Takeda Pharma AG, Pfäffikon, Switzerland

Objective: Chronic obstructive pulmonary disease (COPD) represents a burden on patients and health systems. Roflumilast, an oral, selective phosphodiesterase-4-inhibitor reduces exacerbations and improves lung function in severe/very severe COPD patients with a history of exacerbations. This study aimed to estimate the lifetime cost and outcomes of roflumilast added-on to commonly used COPD regimens in Switzerland.
Methods: A Markov cohort model was developed to simulate COPD progression in patients with disease states of severe, very severe COPD, and death. The exacerbation rate was assumed to be two per year in severe COPD. COPD progression rates were drawn from the published literature. Efficacy was expressed as relative ratios of exacerbation rates associated with roflumilast, derived from a mixed-treatment comparison. A cost-effectiveness analysis was conducted for roflumilast added to long-acting muscarinic antagonists (LAMA), long-acting ß2-agonist/inhaled corticosteroids (LABA/ICS), and LAMA + LABA/ICS. The analysis was conducted from the Swiss payer perspective, with costs and outcomes discounted at 2.5% annually. Parameter uncertainties were explored in one-way and probabilistic sensitivity analyses.
Results: In each of the comparator regimens mean life expectancy was 9.28 years and quality-adjusted life years (QALYs) gained were 6.19. Mean estimated lifetime costs per patient in the comparator arms were CHF 83,364 (LAMA), CHF 88,161 (LABA/ICS), and CHF 95,564 (LAMA + LABA/ICS) respectively. Adding roflumilast resulted in a mean cost per patient per lifetime of CHF 86,754 (LAMA + roflumilast), CHF 91,470 (LABA/ICS + roflumilast), and CHF 99,364 (LAMA + LABA/ICS + roflumilast), respectively. Life-expectancy and quality-adjusted life-expectancy were 9.63 years and 6.47 QALYs (LAMA + roflumilast), 9.64 years and 6.48 QALYs (LABA/ICS + roflumilast), and 9.63 years and 6.47 QALYs (LAMA + LABA/ICS + roflumilast). Incremental cost-effectiveness ratios were CHF 12,313, CHF 11,456, and CHF 13,671 per QALY when roflumilast was added to the three regimens.
Conclusion: Treatment with roflumilast is estimated to reduce the health and economic burden of COPD exacerbations and represent a cost-effective treatment option for patients with frequent exacerbations in Switzerland.

Keywords: COPD, treatment, exacerbations, economic, cost-effectiveness, modeling

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients

Nascimento ESP, Sampaio LMM, Peixoto-Souza FS, Dias FD, Gomes ELFD, Greiffo FR, Ligeiro de Oliveira AP, Stirbulov R, Vieira RP, Costa D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:645-653

Published Date: 23 March 2015

Use of electrical impedance spectroscopy to detect malignant and potentially malignant oral lesions

Murdoch C, Brown BH, Hearnden V, Speight PM, D'Apice K, Hegarty AM, Tidy JA, Healey TJ, Highfield PE, Thornhill MH

International Journal of Nanomedicine 2014, 9:4521-4532

Published Date: 23 September 2014

Troponin elevation in conditions other than acute coronary syndromes

Tanindi A, Cemri M

Vascular Health and Risk Management 2011, 7:597-603

Published Date: 22 September 2011

Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians

Gregory D Salinas, James C Williamson, Ravi Kalhan, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:171-179

Published Date: 28 February 2011